GSK’s Asthma Treatment Exdensur Approved in Japan

GSK PLC (LSE:GSK, NYSE:GSK) has received regulatory approval in Japan for its biologic therapy Exdensur (depemokimab) to treat severe or refractory bronchial asthma and chronic rhinosinusitis with nasal polyps, the company announced today. The approval was grounded in data from the Phase III SWIFT and ANCHOR clinical trials, which assessed the efficacy of twice‑yearly dosing of Exdensur versus placebo on top of standard care. According to GSK, the trial results showed meaningful reductions in asthma exacerbations and significant improvements in nasal polyp size and obstruction measures — key symptoms that impact patients' quality of life. Kaivan Khavandi, GSK’s senior vice president and global head of Respiratory, Immunology & Inflammation R&D, emphasized that with just two doses per year, Exdensur offers physicians an ultra‑long‑acting treatment option capable of delivering sustained suppression of type 2 inflammation. The company has described the treatment as well‑tolerated, with a safety profile comparable to placebo. Japan represents the third major market to approve Exdensur, following earlier authorizations in the United States and the United Kingdom. This latest regulatory milestone marks a significant expansion of treatment options for patients with challenging asthma and related respiratory conditions. #GSK #AsthmaTreatment #Exdensur #PharmaNews #SlimScan #GrowthStocks #CANSLIM